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Abstract
The mammalian brain is extremely sensitive to alterations in cellular homeostasis as a result of
environmental or physiological insults. In particular, hypoxic/ischemic challenges (i.e. reduced oxygen
and/or glucose delivery) cause severe and detrimental alterations in brain function and can trigger
neuronal cell death within minutes. Unfortunately, as we age, oxygen delivery to cells and tissues is
impaired, thereby increasing the susceptibility of neurons to damage. Thus, hypoxic (neuronal)
adaptation is significantly compromised during aging. Many neurological diseases, such as stroke,
Alzheimer's disease (AD), Parkinson's disease and diabetes, are characterized by hypoxia, a state that is
believed to only exacerbate disease progression. However, the contribution of hypoxia and
hypoxia-mediated pathways to neurodegeneration remains unclear. This review discusses current
evidence on the contribution of oxygen deprivation to AD, with an emphasis on hypoxia inducible
transcription factor-1 (HIF-1)-mediated pathways and the association of AD with the cytoskeleton
regulator cyclin-dependent kinase 5. (Part of a multi-author review.).
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The mammalian brain is extremely sensitive to changes in cellular homeostasis as a
result of environmental or physiological insults. In particular, hypoxic/ischemic
challenges (i.e. reduced oxygen and/or glucose delivery) cause severe and detrimental
alterations in brain function, and can trigger neuronal cell death within minutes.
Unfortunately, as we age oxygen delivery to cells and tissues is impaired and as such
the susceptibility of neurons to damage also increases. Thus hypoxic (neuronal)
adaptation is significantly compromised during aging.
Many neurological diseases such as stroke, Alzheimers disease (AD), Parkinsons
disease and diabetes are characterized by hypoxia, a state that is thought to only
exacerbate disease progression. However, the contribution of hypoxia and hypoxia-
mediated pathways to neurodegeneration remains unclear. This review discusses
current evidence of the contribution of oxygen deprivation to AD, with emphasis on
HIF-1 mediated pathways and its association with the cytoskeleton regulator Cdk5.
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3Introduction
Proper neuronal activity is critical for physiological function of the entire organism
and disruption of neuronal function has devastating consequences. Neurons are
extremely dependent on oxygen availability and high vulnerability is observed during
conditions that cause or result in alterations in oxygen supply. Even just a few
minutes of oxygen deprivation initiates significant dysfunction and longer episodes
can ultimately result in the induction of cell death [1].
Unfortunately, as we age oxygen delivery to cells and tissues is somewhat impaired
and thus the susceptibility of neurons to damage also increases. Furthermore cellular
adaptation to hypoxia is significantly compromised with increasing age, and at the
same time an ischemic episode has a more dramatic outcome in old versus young
patients [2, 3]. In line with these findings stroke risk doubles with each decade after
the age of 55 while two thirds of cerebral infarctions are reported in people over the
age of 65 [4]. Increased neuronal vulnerability is also very evident in the sharp rise in
incidence of neurodegenerative diseases that occur in the later stages of life and as
lifespan continues to increase. Indeed, mortality as a result of neurological disorders
constitutes 12% of total deaths globally while nervous system diseases lead to more
hospitalisations than any other disease group including heart disease and cancer,
resulting in a burden on both social and economic sectors of society.
A key characteristic of many neurodegenerative disorders such as Alzheimer’s disease
(AD), Parkinson’s disease and frontotemporal dementias, is the accumulation of
potentially toxic proteins which although present throughout life become neurotoxic
as a result of environmental stimuli including head injury, oxygen deprivation and
oxidative stress. The precise contribution of such stimuli to neurodegeneration
4remains largely unknown but reduced oxygen supply seems to play a key role in being
a cause and/or consequence of neurodegeneration during the aging process.
This review discusses current evidence for the contribution of oxygen deprivation and
HIF-1 mediated pathways to neurodegeneration, with particular emphasis on AD and
the cytoskeleton regulator Cdk5.
Alzheimer’s Pathogenesis
Alzheimer’s disease (AD) is a complex, progressive neurodegenerative disorder. AD
patients show severe memory and cognitive function impairment, which is believed to
be the outcome of disrupted neuronal circuits and severe neuronal loss. The
prevalence of AD is directly related to age [5, 6] and represents a huge healthcare
issue for society, and indeed a growing social and economic burden for the developed
world. Currently the cost of care for patients with AD around the world is
approximately $150 billion annually.
The major pathological hallmarks of AD are large extracellular β−amyloid (Aβ)
plaques and intraneuronal neurofibrillary tangles (NFTs) composed of abnormally
hyperphosphorylated forms of the microtubule-associated protein tau. Aβ is the
cleaved product of the transmembrane amyloid precursor protein (APP). Cleavage of
APP by the β-secretase (β site amyloid precursor protein cleavage enzyme, BACE)
and consequently by the γ− secretase complex results in the formation of two Aβ
isoforms, Aβ40 and Aβ42 that have neurotoxic potential. Interestingly, the presence
of Aβ in the cerebrospinal fluid (CSF) of healthy individuals and also in the media
from neuronal cultures suggests an additional physiological role for Aβ. Indeed
evidence suggests that during the initial phase of AD both Aβ deposition and
5formation of NFTs are the consequence of oxidative stress and help to protect neurons
against injury [7, 8].
However during disease progression it appears that this anti-oxidant capacity becomes
pro-oxidant promoting generation of free radicals, disruption of microtubule
networks, disturbances of axoplasmic transport, synapse loss and eventually neuronal
death. It is therefore argued that Aβ becomes toxic only when the balance between its
production and degradation is disturbed as a result of stressful stimuli. The density of
NFTs correlates with severity of the AD symptoms and a number of proteins, such as
protein kinases cyclin-dependent kinase 5 (Cdk5) and glycogen synthase kinase 3
(GSK3), have been shown to be involved in tau hyperphosphorylation [9, 10].
Alterations in the actin cytoskeleton frequently accompany AD pathology. Actin-rich
inclusions known as Hirano bodies, as well as cofilin-actin rods have been described
in a number of neurodegenerative disorders [11, 12]. Immunohistochemical studies
have revealed that Hirano bodies are mainly composed of actin microfilaments,
although tau, tubulin as well as APP are also present [13].  The number of Hirano
bodies increases as a result of physiological aging, and is further increased in AD
patients, indicating their participation in disease pathogenesis [14]. Cofilin-actin rods,
much smaller aggregates that appear as separate units in AD brains, are also thought
to give rise to Hirano bodies over time [15].
Along with progressive Aβ and NFT accumulation, cytoskeletal and synapse
disruption, AD pathology is further characterized by inflammation as well as deficits
in expression of neurotrophic factors, transcription factors and antioxidant enzymes.
Altogether these multi-faceted events render the disease complex and thus particularly
difficult to treat.
6Hypoxia and AD pathogenesis 
AD is a multifactorial disease where both genetic and environmental factors
contribute to, and accelerate, disease progression. It is now apparent that genetic
predisposition is accountable for only a small number of AD cases. Fully penetrant
mutations leading to protein cleavage and consequent aggregation are responsible for
only 5% of all AD cases and result in familial early onset AD (from 65 years) [16].
Although most cases have no known genetic basis, exposure to other pathogenic
conditions including chronic inflammation, traumatic brain injury, cerebrovasvular
disease, hypoxia/ischemia as well as exposure to pesticides [5, 16-18] could be
contributing factors.
It has previously been shown that individuals who have suffered severe hypoxia or
ischemia are more susceptible to develop AD [19, 20]. Particularly the risk of incident
dementia is elevated in association with illnesses that might cause cerebral hypoxia or
ischemia suggesting that cerebral hypoperfusion may serve as a basis for some cases
of dementia after stroke [20]. Also head injury induces ischemic changes that induce
tau-like pathology subsequent to neuronal damage indicating that such injuries/insults
can lead to relatively rapid induction of APP and amyloidogenic phenotypes even in
the young brain [21]. In vitro, when cortical neurons were treated with Aβ
concomitantly with hypoxic exposure, the number of apoptotic neurons increased
dramatically compared to treatment with Aβ alone [22] indicating that hypoxia itself
accelerates the neuronal death observed in AD brains. Furthermore, hypoxia not only
contributed to plaque formation in an AD transgenic mouse model but also increased
the memory deficit characterizing these mice [23]. Thus impairment of proper oxygen
supply is involved in AD pathogenesis and substantiates clinical observations that
associate hypoxic episodes to AD.
7Despite this, the molecular mechanisms that link hypoxia to AD pathogenesis are not
well defined. Hypoxia/ischemia upregulate APP both at the mRNA and protein level
and lead to subsequent Aβ accumulation [19, 22, 24-27]. It is thought that an
immediate increase in APP levels is a defense mechanism employed to induce
production of the cleaved soluble product APPα that has known neuroprotective
properties [19]. At the same time however, increased APP levels are the source for
generation and accumulation of Aβ that also increases dramatically as a result of
hypoxic injury. Aβ neurotoxic effects are also known to involve alterations in Ca2+
homeostasis, a key event in AD pathogenesis leading to cytoskeletal disruption and
eventually neuronal death [28, 29]. Prolonged hypoxia selectively upregulates L-type
Ca2+ channels, an event that requires Aβ formation since in its absence these channels
are no longer affected by the hypoxic insult [30]. Indeed Aβ interacts directly with the
α1 subunit and hypoxia further promotes this interaction, leading to increased
expression of functional Ca2+ channels at the cell membrane and thus an increase in
Ca2+ influx [31], probably mediated by Ca2+ -permeable AMPA receptors [22]. This
suggests that a feedback loop between Aβ and hypoxia may promote disease
progression. Other evidence shows that brief periods of hypoxia can potentiate the
Aβ-induced expression of the pro-inflammatory markers cyclooxygenase-2 and
presenilin 1 (COX-2 and PS1 respectively) thus accelerating the inflammatory
neuropathology that characterizes AD brains [32].
Taken together these data provide convincing evidence that hypoxia contributes to
AD pathogenesis through amyloidogenesis and Ca2+ dependent mechanisms. However
it is clear that many more studies are needed to fully understand the impact of
hypoxia-mediated changes on neurodegenerative pathologies.
8HIF-1 signaling during AD – A double-edged sword?
At the molecular level, a large percentage of hypoxic responses are controlled by the
hypoxia inducible transcription factor-1 (HIF-1, reviewed by Webb et al. in this
issue). The HIF complex is a heterodimer composed of a constitutively expressed
HIF-1β subunit (also known as aryl hydrocarbon receptor nuclear translocation,
ARNT) and a HIF-1α oxygen regulated subunit [33-37]. Regulation of HIF-1α
activity occurs at different levels including protein stability, phosphorylation, nuclear
translocation and activity, all being influenced by alterations in oxygen levels. Under
normoxic conditions HIF-1α is degraded. In contrast, under hypoxic conditions HIF-
1α is stabilized and translocated to the nucleus where it dimerizes with  ARNT and
subsequently binds to hypoxic binding sites (HBS) of target genes. The HBS is a
conserved consensus sequence (A/G)CGTG within the hypoxic response element
(HRE) present in oxygen-regulated target genes involved in cell survival, glycolysis,
angiogenesis, erythropoiesis, and iron metabolism [38]. Degradation of HIF-1α is
triggered by oxygen-dependent hydroxylation of proline residues located in the
oxygen-dependent degradation domain by a family of prolyl hydroxylases, namely
PHD1, PHD2, and PHD3 [39-41]. These enzymes are specific HIF-1α  proline
hydroxylases that require Fe(II) as a co-factor as well as oxygen and 2-oxoglutarate as
co-substrates [42, 43]. Prolyl hydroxylation promotes the recruitment of the tumor
suppressor protein von Hippel Lindau, which is part of the E3 ligase ubiquitination
complex, priming HIF-1α for degradation in the proteosomes.
Since hypoxia may mediate AD progression is there evidence to suggest that HIF-1
has a role in AD pathology? Over a decade ago it was already apparent that the iron
chelator desferoxamine, that also induces and stabilizes HIF-1 expression, protects
9cultured cells from Aβ [44] and inhibits AD progression in patients [45]. More
recently another metal chelator, clioquinol, was shown to reverse AD-like pathologies
in transgenic mice [45] and induce HIF-1 expression [35]. These studies provided the
first clues to the possible involvement of HIF-1 in neurodegenerative disorders that is
now becoming more widely accepted. However the precise role of the pathway, albeit
positive or negative, remains a matter of debate.
Notably HIF-1-mediated signaling has been implicated in both cell survival and cell
death pathways [46] and the modulation of the HIF pathway seems to be very
complex. During aging HIF induction and signaling pathways are down regulated
[47]. This impairment of important HIF-1 signaling pathways in the aged brain may
render the individual more susceptible to neurodegeneration. Soucek et al. [35]
showed that Aβ  directly induces HIF-1α  expression and activity in vitro.
Interestingly, low levels of Aβ protected neurons from a more aggressive insult via
the induction of HIF-1α pathways and crucially, over-expression of HIF-1α was
sufficient to protect neurons from Aβ neurotoxicity. A very recent study also
demonstrated that HIF-1 levels are further reduced in AD brains in comparison to
age-matched controls [48] again pointing to the possibly detrimental down-regulation
of important HIF target genes. In line with this, the observed decreased expression of
two major brain glucose transporters, GLUT1 and GLUT3, in AD brain was most
probably the result of reduced HIF-1 levels, their main regulator. Furthermore the
decrease in GLUT1 and GLUT3 levels negatively correlated with tau
hyperphosphorylation as well as increased density of neurofibrillary tangles providing
evidence for the involvement of glucose transporters in abnormal tau
hyperphosphorylation and formation of neurofibrillary tangles, both events being
tightly linked to neurodegeneration [48]. Further supporting the idea of detrimental
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down regulation of HIF-1 target genes during disease, Chong et al. [49] provided
evidence for a neuroprotective role of erythropoietin (Epo), a well described HIF-1
target, against Aβ toxicity in hippocampal neurons in vitro. In their study Epo was
necessary and sufficient to prevent Αβ induced apoptotic death both in early and later
stages of neurodegeneration via the expression and translocation of NF-kB p65.
Similarly levels of Epo in the cerebrospinal fluid of AD patients are reduced, or in the
same range, as control brains [50], a surprising finding in light of upregulation of Epo
in adults with traumatic brain injury or depression. This once more indicated that a
deficiency of protective endogenous Epo in dementia, again presumably due to
decreased HIF expression, may contribute to disease progression.
Lack of or insufficient neuroprotective effects of vascular endothelial growth factor
(VEGF), another infamous HIF target gene, has also been proposed to accelerate
neurodegenerative disorders [51]. Indeed treatment of motorneuron degeneration by
intracerebroventricular delivery of VEGF in a rat model of amyotrophic lateral
sclerosis had therapeutic effects [52] hinting perhaps that VEGF may have an
analogous role in AD. Polymorphisms in the promoter region of VEGF were also
suggested to be associated with increased risk of developing AD [53] although this
finding was not confirmed in subsequent studies [54, 55]. Notably, until now the
precise contribution of this important growth factor to AD progression remains
elusive.
Overall it is perhaps not so surprising that, as a result of the above studies, some
scientists have proposed hypoxic preconditioning as an alternative therapy to prevent
deterioration of neuronal cells in AD [56]. However since contradictory studies have
also been published (reviewed below) and it has been shown in other studies that the
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manipulation of hypoxic pathways can have many different outcomes, much more
evidence is needed to give such potential therapies sufficient backing.
In complete contrast to the aforementioned data, conflicting evidence suggests that
induction of HIF pathways as a consequence of AD could be detrimental for neuronal
survival by inducing apoptotic genes and pro-inflammatory proteins. Recently
evidence has shown a definite link between ischemia/hypoxia, HIF-1 and APP
processing/Aβ production. Notably, Zhang et al. [57] showed that during acute
hypoxia HIF-1 binding to the BACE1 promoter induced BACE1 expression and
resulted in increased Aβ production in neuroblastoma cells. Moreover, HIF-1α
deficiency reduced BACE1 expression in the cortex and hippocampus of transgenic
mice pointing to HIF-1 as the primary mediator of hypoxic induction of BACE1.
Wang et al. [58] also showed that APH-1A expression and subsequent γ-secretase
mediated Aβ and Notch generation are also regulated by HIF-1 binding to the APH-
1A promoter during hypoxia. Since inhibiting or reducing levels of secretase activity
decreases production of Aβ in the absence of severe detrimental phenotypes [59, 60],
it could be speculated that HIF-1 inhibition may provide an alternative approach for
therapeutic targeting.
This is further substantiated by the fact that brief periods of hypoxia that can
potentiate the Aβ-induced neural expression of the pro-inflammatory markers
cyclooxygenase-2 and presenilin 1 (COX-2 and PS1 respectively), and accelerate the
inflammatory neuropathology that characterizes AD brains, most probably also occurs
through HIF signaling pathways [32]. In addition, potential HIF binding sites
identified on presenilin promoter regions further imply that HIF-1 may be involved in
stress-mediated PS1 transcriptional regulation [61]. Thus episodic hypoxia during
aging may drive expression of COX-2, PS1 and related genes by way of HIF-1
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signaling that ultimately contributes, cumulatively, to inflammatory responses and
amyloidogenic neuropathology.
Another AD event linked to HIF-1 is the oxidative stress-induced accumulation of
Aβ  and subsequent activation of the pro-death gene BNIP3 in primary cortical
neurons [62]  Knockdown of HIF-1α by RNA interference not only inhibited BNIP3
induction but also reduced Aβ induced neuronal death. Thus HIF-1 seems to mediate
a potentially pathological role of BNIP3 in AD etiology. That hypoxia/HIF-1
signaling is involved in amyloidogenic processing of APP and subsequent
downstream events also provides good rationale for increased incidence of AD and
neurodegeneration after cerebral ischemia and stroke. However despite this body of
data suggesting that HIF-1 inhibition may also be a good therapeutic strategy, more
evidence is needed to understand if the role of HIF-1 in neurodegeneration, especially
in vivo, is beneficial or detrimental.
Thus the overall contribution of HIF signaling pathways per se to progression of
neurodegenerative disease is still very hazy. On the one hand it seems that aged
neurons with attenuated HIF signaling neuroprotective pathways are more susceptible
to neurodegeneration. On the other hand, sustained activation of HIF also seems to be
harmful and can accentuate undesirable disease characteristics. From current research
it seems likely that the role of HIF in neurodegeneration may greatly depend on
whether it is the cause or the consequence of disease progression.
Oxygen deprivation-mediated cytoskeletal alterations and AD
Uncertainty still surrounds the sequence of events that lead to AD pathogenesis.
Nevertheless cytoskeletal abnormalities ranging from the formation of NFTs to axonal
13
and dendritic atrophy, as well as deregulation of cytoskeletal-regulatory proteins in
post-mortem AD brains, suggest the cytoskeleton is an important player in the
disease. Alterations in the actin cytoskeleton have been linked with both hypoxic
injury and neurodegeneration [63]. In neurons dynamic regulation of actin
microfilament polymerisation is implicated in maintaining dendritic structure and
notably the number of dendritic spines is significantly decreased in Alzheimer’s
neurons, indicating an active role for actin in disease progression [64]. Similarly,
oxygen deprivation in the brain also causes neurons to undergo morphological
changes including process retraction and loss of shape partially attributable to
depolymerisation of actin filaments [65]. Thus similar cytoskeletal abnormalities
typify both oxygen-deprived and AD neurons. Hypoxia causes decreased neuritic
sprouting, impaired mitochondrial function and reduced expression of proteins that
are required to maintain synaptic connections and ultimately neuronal death [66].
Cofilins are actin-binding proteins regulating assembly and disassembly of actin
filaments [67]. Following a stressful stimulus cofilins undergo changes in
phosphorylation leading to the formation of rod-shaped actin bundles, commonly
known as rods that contribute to AD pathogenesis by inhibiting vesicle transport and
disrupting synaptic function [15]. Interestingly rods are also rapidly formed in
response to anoxia [68] indicating that alterations in oxygen levels may be one
underlying event contributing to the synaptic deficits responsible for memory
impairment in AD patients. Independent studies have further documented a direct
effect of oxygen deprivation on neurofilament breakdown and tau
hyperphophosphorylation both in vivo and in vitro [69, 70]. Notably, cytoskeletal
alterations are also documented in a number of other (neuro)pathogenic diseases and
disorders characterised by oxygen deprivation [71].
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Cdk5, hypoxic signaling and HIF-1
Neurofilaments (NFs) are cytoskeletal intermediate filaments exclusively expressed in
neurons that provide rigidity, cell shape and facilitate intracellular transport and
guidance of axons and dendrites. Abnormal accumulation of NFs is frequently
detected in neurodegenerative disorders and is considered a major hallmark of
neuronal dysfunction. NFTs are composed of abnormally modified and
hyperphosphorylated tau, NFs and other cytoskeletal proteins. The cause of this
aberrant transformation is not fully understood but has been attributed to pertubations
in the normal balance of kinases and phosphatases. In particular the kinases GSK3
and Cdk5, both of which have been co-purified with microtubules, play significant
roles in cytoskeletal protein hyperphosphorylation and NFT generation [72, 73].
Cyclin dependent kinase 5 (Cdk5), a proline-directed serine/threonine kinase, is an
important regulator of the neuronal cytoskeleton and another key player in
neurodegeneration and AD pathogenesis [5]. Under normal conditions membrane-
bound Cdk5 is critical for maintenance of neuronal survival. It exerts its function
through phosphorylation of a number of target proteins that include cytoskeletal
proteins, signal transduction kinases and transcription factors [74]. Cdk5 is associated
with two non-cyclin activators p35 and p39 that restrict Cdk5 activity to neurons,
keep the protein attached to the membrane and activate the protein via
phosphorylation [75]. However under pathological conditions, Cdk5 activity is
deregulated. First an increase in Ca2+ influx stimulates the activation of calpains, a
family of proteases with a key role in maintaining the cytoskeletal architecture [76].
Calpain then cleaves p35 and p39, the main regulators of Cdk5, resulting in the
generation of truncated products p25 and p29 respectively. This cleavage leads to loss
of the protein complex membrane attachment, mislocalisation of Cdk5 and
deregulation of its activity [77]. The hyperactivation of Cdk5 is tightly linked to
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Alzheimer’s pathogenesis being observed in postmortem brains and in neurons
exhibiting NFT. Cdk5 has also been shown to physically interact and phosphorylate
tau in vivo [78, 79].
It however appears that Cdk5 regulation is also complex since some recent data have
suggested that transient upregulation of Cdk5 activity in the adult brain, as a result of
DNA damage, is beneficial and protects neurons from death. Studies have shown that
Cdk5 phosphorylates and inhibits c-Jun N-terminal kinase thus countering the
induction of apoptotic signals [80]. Furthermore O’Hare et al. [81] showed that
cytoplasmic Cdk5 is neuroprotective in models of excitotoxicity and DNA damage in
vitro, whereas nuclear Cdk5 is harmful and contributes to neuronal death. Thus
localisation may also play a key role in determining the pro-survival or pro-death
functions of the kinase. Notably, the molecular mechanisms that regulate the
beneficial versus detrimental effects of Cdk5 are still to be determined.
It is now apparent that Cdk5/p35 may be involved in the regulation of oxidative
stress-mediated pathways [82]. The first evidence of a role for the Cdk5/p35 complex
in neuronal responses to oxygen deprivation came from research in Drosophila almost
a decade ago [83]. Since then a number of studies have reported upregulation of the
complex in models of ischemia both in vivo and in vitro [84-87] additionally
implicating modulation of this pathway during ischemic injury. Interestingly, similar
to HIF-1 regulation, oxidative stress induces activity of Cdk5 and overall expression
is downregulated with age in the human brain [88]. Furthermore Tamada et al
demonstrated that p35 is cleaved during hypoxia as a result of calpain activation in
mouse retina neurons [89]. Vartianen et al. [90] also showed that Cdk5 activity and
p35 expression play an important role in aspirin induced tolerance in rat neurons
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against hypoxia/reoxygenation damage.
Very recent results from our group show that oxygen deprivation alone induces
cytoskeletal rearrangement and distinctly modulates both components of the complex
(Antoniou et al., unpublished data), in agreement with another study showing
increased activation of Cdk5 in neuroblastoma cells subjected to chemical oxidative
stress [87]. Thus hypoxia and oxidative stress both significantly alter Cdk5 activity
and this could have important consequences for neuronal function and survival since
the localisation of Cdk5 has been suggested to determine neuronal fate [81].
Accordingly hypoxia caused redistribution of Cdk5 to mainly the neuronal soma,
signifying an altered function for the kinase and possible interaction with aberrant
proteins. The nuclear translocation of Cdk5 can modulate transcription factors that are
involved in cell death pathways [81] and importantly, we have observed that Cdk5
function can regulate the expression of HIF-1 in primary cortical neurons during
hypoxic exposure. Notably, pharmacological inhibition of Cdk5 by roscovitine
attenuated HIF-1α induction in a time-dependent manner and additionally induced
dramatic downregulation of Epo mRNA hypoxic induction in primary cortical
neurons (Antoniou et al., unpublished data). In contrast the surprising inability of
roscovitine treatment to alter VEGF mRNA induction suggests that Cdk5
differentially modulates hypoxic-induced signaling pathways. This observation could
be of importance for understanding mechanisms of neuronal survival and progression
of neurodegenerative disorders in general, as well as treatment therapies as a whole.
Indeed, roscovitine treatment exacerbated cell death during chronic hypoxia
suggesting the requirement of Cdk5 function in modulation of neuronal survival
pathways during long-term injury/insult presumably via modulation of HIF-1
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signalling. As such these pathways may be intertwined with pathogenetic disease
progression that occurs over extended time periods. Unfortunately the mechanism of
Cdk5-regulated HIF induction is still unclear and how specificity for target gene
induction is determined remains perplexing. These and other important questions are
now being fully addressed in our ongoing studies. Nevertheless, our current evidence
supports the notion that Cdk5, a regulator of AD pathogenesis, does play a beneficial
role during hypoxic events and interacts with HIF-1 to modulate neuronal fate during
neurodegenerative-related processes. Taken together these findings underline the
importance of better understanding of the overlap and contribution of HIF-1 pathways
to AD.
Summary
It is blatantly clear that increased incidence of neurodegenerative diseases is a
growing problem for the world. Although the precise mechanisms of age-dependent
neuronal susceptibility are unknown, decreased expression of cellular defence genes
in the aged brain make it less able to withstand injury. The current challenge is to find
ways to increase the adaptive reserve of the organism to combat such age-related
deficits and support or promote normal neuronal function. Oxygen deprivation seems
to characterise most pathological processes and diseases, and in this regard
neurodegeneration is no exception. How oxygen deprivation affects the progression of
such disorders remains unclear, but it seems likely that it can only serve to exhaust the
adaptive reserves of the brain. Thus it is more and more crucial to explore the
contribution of hypoxic-mediated pathways to age-related pathogenesis to gain more
knowledge on how to intervene during disease progression. In the future perhaps
18
manipulation of hypoxia and/or HIF-modulated signalling will provide new hope for
development of novel therapies urgently needed to combat neurodegenerative disease.
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